nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—SLC47A2—Mitoxantrone—hematologic cancer	0.116	0.17	CbGbCtD
Ondansetron—SLC47A1—Imatinib—hematologic cancer	0.0608	0.0892	CbGbCtD
Ondansetron—SLC47A1—Mitoxantrone—hematologic cancer	0.0482	0.0708	CbGbCtD
Ondansetron—CYP1A2—Anagrelide—hematologic cancer	0.0184	0.027	CbGbCtD
Ondansetron—CYP2E1—Thalidomide—hematologic cancer	0.0118	0.0173	CbGbCtD
Ondansetron—CYP2C9—Bexarotene—hematologic cancer	0.0115	0.0169	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0107	0.0158	CbGbCtD
Ondansetron—CYP3A7—Ifosfamide—hematologic cancer	0.0107	0.0158	CbGbCtD
Ondansetron—CYP3A7—Imatinib—hematologic cancer	0.0102	0.015	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0102	0.015	CbGbCtD
Ondansetron—CYP2E1—Dacarbazine—hematologic cancer	0.0101	0.0149	CbGbCtD
Ondansetron—CYP3A5—Daunorubicin—hematologic cancer	0.01	0.0147	CbGbCtD
Ondansetron—CYP2D6—Lomustine—hematologic cancer	0.00976	0.0143	CbGbCtD
Ondansetron—CYP1A2—Carmustine—hematologic cancer	0.00966	0.0142	CbGbCtD
Ondansetron—CYP2C9—Idarubicin—hematologic cancer	0.00951	0.014	CbGbCtD
Ondansetron—CYP3A5—Thalidomide—hematologic cancer	0.00914	0.0134	CbGbCtD
Ondansetron—CYP3A5—Teniposide—hematologic cancer	0.00872	0.0128	CbGbCtD
Ondansetron—CYP2D6—Idarubicin—hematologic cancer	0.0087	0.0128	CbGbCtD
Ondansetron—CYP1A2—Methoxsalen—hematologic cancer	0.00821	0.0121	CbGbCtD
Ondansetron—CYP3A5—Ifosfamide—hematologic cancer	0.00805	0.0118	CbGbCtD
Ondansetron—CYP2E1—Mitoxantrone—hematologic cancer	0.00785	0.0115	CbGbCtD
Ondansetron—CYP1A2—Bortezomib—hematologic cancer	0.00781	0.0115	CbGbCtD
Ondansetron—CYP3A5—Imatinib—hematologic cancer	0.00769	0.0113	CbGbCtD
Ondansetron—CYP1A2—Daunorubicin—hematologic cancer	0.00747	0.011	CbGbCtD
Ondansetron—CYP2D6—Hydroxyurea—hematologic cancer	0.0074	0.0109	CbGbCtD
Ondansetron—CYP1A2—Alitretinoin—hematologic cancer	0.00732	0.0107	CbGbCtD
Ondansetron—CYP2C9—Bortezomib—hematologic cancer	0.00704	0.0103	CbGbCtD
Ondansetron—CYP1A2—Thalidomide—hematologic cancer	0.0068	0.00999	CbGbCtD
Ondansetron—CYP3A4—Bexarotene—hematologic cancer	0.00668	0.0098	CbGbCtD
Ondansetron—CYP2D6—Bortezomib—hematologic cancer	0.00643	0.00945	CbGbCtD
Ondansetron—CYP3A7—Irinotecan—hematologic cancer	0.0064	0.0094	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.0064	0.0094	CbGbCtD
Ondansetron—CYP3A4—Busulfan—hematologic cancer	0.00621	0.00911	CbGbCtD
Ondansetron—CYP3A4—Lomustine—hematologic cancer	0.00621	0.00911	CbGbCtD
Ondansetron—CYP3A5—Dasatinib—hematologic cancer	0.00617	0.00907	CbGbCtD
Ondansetron—CYP2C9—Thalidomide—hematologic cancer	0.00613	0.009	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—hematologic cancer	0.00585	0.00859	CbGbCtD
Ondansetron—CYP2C9—Teniposide—hematologic cancer	0.00585	0.00859	CbGbCtD
Ondansetron—CYP1A2—Imatinib—hematologic cancer	0.00572	0.0084	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00559	0.00822	CbGbCtD
Ondansetron—CYP3A7—Vincristine—hematologic cancer	0.00559	0.00822	CbGbCtD
Ondansetron—CYP3A4—Thiotepa—hematologic cancer	0.00553	0.00812	CbGbCtD
Ondansetron—CYP2C9—Ifosfamide—hematologic cancer	0.0054	0.00793	CbGbCtD
Ondansetron—CYP2C9—Imatinib—hematologic cancer	0.00516	0.00757	CbGbCtD
Ondansetron—CYP2E1—Etoposide—hematologic cancer	0.00495	0.00727	CbGbCtD
Ondansetron—CYP3A5—Irinotecan—hematologic cancer	0.0048	0.00705	CbGbCtD
Ondansetron—CYP2D6—Imatinib—hematologic cancer	0.00471	0.00692	CbGbCtD
Ondansetron—CYP2C9—Nilotinib—hematologic cancer	0.00468	0.00688	CbGbCtD
Ondansetron—CYP1A2—Dasatinib—hematologic cancer	0.0046	0.00675	CbGbCtD
Ondansetron—CYP3A4—Methoxsalen—hematologic cancer	0.0043	0.00632	CbGbCtD
Ondansetron—CYP2D6—Nilotinib—hematologic cancer	0.00428	0.00629	CbGbCtD
Ondansetron—CYP2D6—Vinorelbine—hematologic cancer	0.00425	0.00624	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00422	0.00619	CbGbCtD
Ondansetron—CYP3A7—Dexamethasone—hematologic cancer	0.00422	0.00619	CbGbCtD
Ondansetron—CYP3A5—Vincristine—hematologic cancer	0.0042	0.00616	CbGbCtD
Ondansetron—CYP3A4—Bortezomib—hematologic cancer	0.00409	0.00601	CbGbCtD
Ondansetron—CYP2E1—Dexamethasone—hematologic cancer	0.00407	0.00598	CbGbCtD
Ondansetron—CYP3A4—Daunorubicin—hematologic cancer	0.00391	0.00575	CbGbCtD
Ondansetron—CYP3A5—Etoposide—hematologic cancer	0.00385	0.00565	CbGbCtD
Ondansetron—CYP3A4—Cytarabine—hematologic cancer	0.00345	0.00507	CbGbCtD
Ondansetron—CYP3A4—Teniposide—hematologic cancer	0.0034	0.00499	CbGbCtD
Ondansetron—CYP3A5—Dexamethasone—hematologic cancer	0.00316	0.00464	CbGbCtD
Ondansetron—CYP3A4—Ifosfamide—hematologic cancer	0.00314	0.00461	CbGbCtD
Ondansetron—CYP3A4—Imatinib—hematologic cancer	0.003	0.0044	CbGbCtD
Ondansetron—CYP1A2—Etoposide—hematologic cancer	0.00286	0.0042	CbGbCtD
Ondansetron—CYP3A4—Ruxolitinib—hematologic cancer	0.00282	0.00415	CbGbCtD
Ondansetron—CYP3A4—Nilotinib—hematologic cancer	0.00272	0.004	CbGbCtD
Ondansetron—CYP3A4—Vinorelbine—hematologic cancer	0.0027	0.00397	CbGbCtD
Ondansetron—CYP2C9—Cisplatin—hematologic cancer	0.00262	0.00385	CbGbCtD
Ondansetron—CYP2D6—Vinblastine—hematologic cancer	0.00262	0.00384	CbGbCtD
Ondansetron—CYP3A4—Triamcinolone—hematologic cancer	0.00247	0.00363	CbGbCtD
Ondansetron—CYP3A4—Dasatinib—hematologic cancer	0.00241	0.00354	CbGbCtD
Ondansetron—CYP3A4—Mitoxantrone—hematologic cancer	0.00238	0.00349	CbGbCtD
Ondansetron—CYP2C9—Dexamethasone—hematologic cancer	0.00212	0.00311	CbGbCtD
Ondansetron—CYP3A4—Betamethasone—hematologic cancer	0.00212	0.00311	CbGbCtD
Ondansetron—CYP3A4—Prednisolone—hematologic cancer	0.00209	0.00307	CbGbCtD
Ondansetron—CYP3A4—Prednisone—hematologic cancer	0.00198	0.0029	CbGbCtD
Ondansetron—CYP2D6—Dexamethasone—hematologic cancer	0.00194	0.00285	CbGbCtD
Ondansetron—CYP3A4—Irinotecan—hematologic cancer	0.00187	0.00275	CbGbCtD
Ondansetron—CYP3A4—Vinblastine—hematologic cancer	0.00166	0.00244	CbGbCtD
Ondansetron—CYP3A4—Vincristine—hematologic cancer	0.00164	0.0024	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—hematologic cancer	0.00161	0.00236	CbGbCtD
Ondansetron—CYP3A4—Etoposide—hematologic cancer	0.0015	0.0022	CbGbCtD
Ondansetron—CYP3A4—Dexamethasone—hematologic cancer	0.00123	0.00181	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—hematologic cancer	0.00102	0.0015	CbGbCtD
Ondansetron—HTR3A—hematopoietic system—hematologic cancer	0.000924	0.0602	CbGeAlD
Ondansetron—SLC47A1—hematopoietic system—hematologic cancer	0.000907	0.0592	CbGeAlD
Ondansetron—OPRM1—hematopoietic system—hematologic cancer	0.000847	0.0552	CbGeAlD
Ondansetron—SLC47A1—gonad—hematologic cancer	0.00069	0.045	CbGeAlD
Ondansetron—HTR1A—hematopoietic system—hematologic cancer	0.000625	0.0408	CbGeAlD
Ondansetron—HTR3A—blood—hematologic cancer	0.000612	0.0399	CbGeAlD
Ondansetron—SLC47A1—blood—hematologic cancer	0.000601	0.0392	CbGeAlD
Ondansetron—OPRM1—blood—hematologic cancer	0.000561	0.0366	CbGeAlD
Ondansetron—KCNH2—hematopoietic system—hematologic cancer	0.000557	0.0363	CbGeAlD
Ondansetron—HTR3A—lung—hematologic cancer	0.000536	0.035	CbGeAlD
Ondansetron—SLC47A1—lung—hematologic cancer	0.000527	0.0344	CbGeAlD
Ondansetron—SLC47A1—testis—hematologic cancer	0.000497	0.0324	CbGeAlD
Ondansetron—CYP1A2—hematopoietic system—hematologic cancer	0.000477	0.0311	CbGeAlD
Ondansetron—OPRM1—testis—hematologic cancer	0.000464	0.0303	CbGeAlD
Ondansetron—CYP3A5—hematopoietic system—hematologic cancer	0.00046	0.03	CbGeAlD
Ondansetron—CYP2C9—hematopoietic system—hematologic cancer	0.000452	0.0295	CbGeAlD
Ondansetron—CYP2E1—hematopoietic system—hematologic cancer	0.000429	0.028	CbGeAlD
Ondansetron—KCNH2—blood—hematologic cancer	0.000369	0.024	CbGeAlD
Ondansetron—SLC47A1—lymph node—hematologic cancer	0.00036	0.0235	CbGeAlD
Ondansetron—KCNH2—bone marrow—hematologic cancer	0.000357	0.0233	CbGeAlD
Ondansetron—CYP3A4—hematopoietic system—hematologic cancer	0.000345	0.0225	CbGeAlD
Ondansetron—CYP2D6—hematopoietic system—hematologic cancer	0.000339	0.0221	CbGeAlD
Ondansetron—CYP1A2—blood—hematologic cancer	0.000316	0.0206	CbGeAlD
Ondansetron—KCNH2—testis—hematologic cancer	0.000305	0.0199	CbGeAlD
Ondansetron—CYP3A5—blood—hematologic cancer	0.000305	0.0199	CbGeAlD
Ondansetron—CYP2C9—blood—hematologic cancer	0.0003	0.0195	CbGeAlD
Ondansetron—CYP2E1—blood—hematologic cancer	0.000284	0.0185	CbGeAlD
Ondansetron—CYP1A2—lung—hematologic cancer	0.000277	0.018	CbGeAlD
Ondansetron—CYP3A5—lung—hematologic cancer	0.000267	0.0174	CbGeAlD
Ondansetron—CYP2E1—lung—hematologic cancer	0.000249	0.0162	CbGeAlD
Ondansetron—CYP2E1—testis—hematologic cancer	0.000235	0.0153	CbGeAlD
Ondansetron—CYP3A4—blood—hematologic cancer	0.000229	0.0149	CbGeAlD
Ondansetron—CYP2D6—blood—hematologic cancer	0.000225	0.0147	CbGeAlD
Ondansetron—KCNH2—lymph node—hematologic cancer	0.000221	0.0144	CbGeAlD
Ondansetron—CYP2D6—testis—hematologic cancer	0.000186	0.0121	CbGeAlD
Ondansetron—Hepatobiliary disease—Doxorubicin—hematologic cancer	3.55e-05	0.000156	CcSEcCtD
Ondansetron—Hypotension—Betamethasone—hematologic cancer	3.55e-05	0.000156	CcSEcCtD
Ondansetron—Hypotension—Dexamethasone—hematologic cancer	3.55e-05	0.000156	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—hematologic cancer	3.53e-05	0.000155	CcSEcCtD
Ondansetron—Vomiting—Mitoxantrone—hematologic cancer	3.53e-05	0.000155	CcSEcCtD
Ondansetron—Vomiting—Irinotecan—hematologic cancer	3.53e-05	0.000155	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—hematologic cancer	3.51e-05	0.000154	CcSEcCtD
Ondansetron—Convulsion—Prednisone—hematologic cancer	3.51e-05	0.000154	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—hematologic cancer	3.51e-05	0.000154	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—hematologic cancer	3.5e-05	0.000154	CcSEcCtD
Ondansetron—Rash—Irinotecan—hematologic cancer	3.5e-05	0.000154	CcSEcCtD
Ondansetron—Rash—Mitoxantrone—hematologic cancer	3.5e-05	0.000154	CcSEcCtD
Ondansetron—Dermatitis—Irinotecan—hematologic cancer	3.49e-05	0.000153	CcSEcCtD
Ondansetron—Dermatitis—Mitoxantrone—hematologic cancer	3.49e-05	0.000153	CcSEcCtD
Ondansetron—Chills—Methotrexate—hematologic cancer	3.49e-05	0.000153	CcSEcCtD
Ondansetron—Headache—Mitoxantrone—hematologic cancer	3.47e-05	0.000153	CcSEcCtD
Ondansetron—Headache—Irinotecan—hematologic cancer	3.47e-05	0.000153	CcSEcCtD
Ondansetron—Feeling abnormal—Triamcinolone—hematologic cancer	3.45e-05	0.000151	CcSEcCtD
Ondansetron—Diarrhoea—Cisplatin—hematologic cancer	3.44e-05	0.000151	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—hematologic cancer	3.44e-05	0.000151	CcSEcCtD
Ondansetron—Anxiety—Prednisone—hematologic cancer	3.44e-05	0.000151	CcSEcCtD
Ondansetron—Vomiting—Gemcitabine—hematologic cancer	3.43e-05	0.000151	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—hematologic cancer	3.43e-05	0.000151	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.42e-05	0.00015	CcSEcCtD
Ondansetron—Paraesthesia—Dexamethasone—hematologic cancer	3.41e-05	0.00015	CcSEcCtD
Ondansetron—Paraesthesia—Betamethasone—hematologic cancer	3.41e-05	0.00015	CcSEcCtD
Ondansetron—Discomfort—Prednisone—hematologic cancer	3.41e-05	0.00015	CcSEcCtD
Ondansetron—Rash—Gemcitabine—hematologic cancer	3.41e-05	0.00015	CcSEcCtD
Ondansetron—Dermatitis—Gemcitabine—hematologic cancer	3.4e-05	0.000149	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—hematologic cancer	3.4e-05	0.000149	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—hematologic cancer	3.4e-05	0.000149	CcSEcCtD
Ondansetron—Erythema—Methotrexate—hematologic cancer	3.39e-05	0.000149	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—hematologic cancer	3.38e-05	0.000149	CcSEcCtD
Ondansetron—Headache—Gemcitabine—hematologic cancer	3.38e-05	0.000149	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—hematologic cancer	3.38e-05	0.000148	CcSEcCtD
Ondansetron—Flushing—Epirubicin—hematologic cancer	3.38e-05	0.000148	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—hematologic cancer	3.37e-05	0.000148	CcSEcCtD
Ondansetron—Hypersensitivity—Prednisolone—hematologic cancer	3.35e-05	0.000147	CcSEcCtD
Ondansetron—Urticaria—Triamcinolone—hematologic cancer	3.32e-05	0.000146	CcSEcCtD
Ondansetron—Asthenia—Etoposide—hematologic cancer	3.31e-05	0.000145	CcSEcCtD
Ondansetron—Body temperature increased—Triamcinolone—hematologic cancer	3.31e-05	0.000145	CcSEcCtD
Ondansetron—Anaphylactic shock—Prednisone—hematologic cancer	3.31e-05	0.000145	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—hematologic cancer	3.3e-05	0.000145	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—hematologic cancer	3.29e-05	0.000144	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—hematologic cancer	3.28e-05	0.000144	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.28e-05	0.000144	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.28e-05	0.000144	CcSEcCtD
Ondansetron—Fatigue—Dexamethasone—hematologic cancer	3.27e-05	0.000144	CcSEcCtD
Ondansetron—Fatigue—Betamethasone—hematologic cancer	3.27e-05	0.000144	CcSEcCtD
Ondansetron—Chills—Epirubicin—hematologic cancer	3.27e-05	0.000143	CcSEcCtD
Ondansetron—Pruritus—Etoposide—hematologic cancer	3.26e-05	0.000143	CcSEcCtD
Ondansetron—Shock—Prednisone—hematologic cancer	3.25e-05	0.000143	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—hematologic cancer	3.25e-05	0.000143	CcSEcCtD
Ondansetron—Pain—Betamethasone—hematologic cancer	3.25e-05	0.000143	CcSEcCtD
Ondansetron—Pain—Dexamethasone—hematologic cancer	3.25e-05	0.000143	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—hematologic cancer	3.24e-05	0.000143	CcSEcCtD
Ondansetron—Nervous system disorder—Prednisone—hematologic cancer	3.24e-05	0.000142	CcSEcCtD
Ondansetron—Tachycardia—Prednisone—hematologic cancer	3.23e-05	0.000142	CcSEcCtD
Ondansetron—Skin disorder—Prednisone—hematologic cancer	3.21e-05	0.000141	CcSEcCtD
Ondansetron—Vomiting—Cisplatin—hematologic cancer	3.2e-05	0.000141	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—hematologic cancer	3.19e-05	0.00014	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—hematologic cancer	3.18e-05	0.00014	CcSEcCtD
Ondansetron—Rash—Cisplatin—hematologic cancer	3.17e-05	0.000139	CcSEcCtD
Ondansetron—Dermatitis—Cisplatin—hematologic cancer	3.17e-05	0.000139	CcSEcCtD
Ondansetron—Erythema—Epirubicin—hematologic cancer	3.17e-05	0.000139	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—hematologic cancer	3.16e-05	0.000139	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—hematologic cancer	3.15e-05	0.000138	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—hematologic cancer	3.14e-05	0.000138	CcSEcCtD
Ondansetron—Feeling abnormal—Betamethasone—hematologic cancer	3.13e-05	0.000137	CcSEcCtD
Ondansetron—Feeling abnormal—Dexamethasone—hematologic cancer	3.13e-05	0.000137	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—hematologic cancer	3.12e-05	0.000137	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—hematologic cancer	3.12e-05	0.000137	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—hematologic cancer	3.12e-05	0.000137	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.1e-05	0.000136	CcSEcCtD
Ondansetron—Gastrointestinal pain—Betamethasone—hematologic cancer	3.1e-05	0.000136	CcSEcCtD
Ondansetron—Hypersensitivity—Triamcinolone—hematologic cancer	3.08e-05	0.000135	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—hematologic cancer	3.05e-05	0.000134	CcSEcCtD
Ondansetron—Malaise—Methotrexate—hematologic cancer	3.05e-05	0.000134	CcSEcCtD
Ondansetron—Dizziness—Etoposide—hematologic cancer	3.05e-05	0.000134	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—hematologic cancer	3.04e-05	0.000134	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—hematologic cancer	3.03e-05	0.000133	CcSEcCtD
Ondansetron—Chills—Doxorubicin—hematologic cancer	3.02e-05	0.000133	CcSEcCtD
Ondansetron—Urticaria—Betamethasone—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Ondansetron—Urticaria—Dexamethasone—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Ondansetron—Dizziness—Prednisolone—hematologic cancer	3.01e-05	0.000132	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—hematologic cancer	3.01e-05	0.000132	CcSEcCtD
Ondansetron—Asthenia—Triamcinolone—hematologic cancer	3e-05	0.000132	CcSEcCtD
Ondansetron—Body temperature increased—Betamethasone—hematologic cancer	3e-05	0.000132	CcSEcCtD
Ondansetron—Abdominal pain—Betamethasone—hematologic cancer	3e-05	0.000132	CcSEcCtD
Ondansetron—Abdominal pain—Dexamethasone—hematologic cancer	3e-05	0.000132	CcSEcCtD
Ondansetron—Body temperature increased—Dexamethasone—hematologic cancer	3e-05	0.000132	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—hematologic cancer	2.99e-05	0.000131	CcSEcCtD
Ondansetron—Paraesthesia—Prednisone—hematologic cancer	2.97e-05	0.00013	CcSEcCtD
Ondansetron—Pruritus—Triamcinolone—hematologic cancer	2.96e-05	0.00013	CcSEcCtD
Ondansetron—Cough—Methotrexate—hematologic cancer	2.95e-05	0.00013	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—hematologic cancer	2.94e-05	0.000129	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—hematologic cancer	2.93e-05	0.000129	CcSEcCtD
Ondansetron—Vomiting—Etoposide—hematologic cancer	2.93e-05	0.000129	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—hematologic cancer	2.93e-05	0.000129	CcSEcCtD
Ondansetron—Agitation—Epirubicin—hematologic cancer	2.91e-05	0.000128	CcSEcCtD
Ondansetron—Rash—Etoposide—hematologic cancer	2.91e-05	0.000128	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—hematologic cancer	2.91e-05	0.000128	CcSEcCtD
Ondansetron—Headache—Etoposide—hematologic cancer	2.89e-05	0.000127	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—hematologic cancer	2.89e-05	0.000127	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—hematologic cancer	2.88e-05	0.000127	CcSEcCtD
Ondansetron—Rash—Prednisolone—hematologic cancer	2.87e-05	0.000126	CcSEcCtD
Ondansetron—Dermatitis—Prednisolone—hematologic cancer	2.87e-05	0.000126	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.86e-05	0.000126	CcSEcCtD
Ondansetron—Malaise—Epirubicin—hematologic cancer	2.86e-05	0.000126	CcSEcCtD
Ondansetron—Fatigue—Prednisone—hematologic cancer	2.85e-05	0.000125	CcSEcCtD
Ondansetron—Headache—Prednisolone—hematologic cancer	2.85e-05	0.000125	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—hematologic cancer	2.85e-05	0.000125	CcSEcCtD
Ondansetron—Syncope—Epirubicin—hematologic cancer	2.84e-05	0.000125	CcSEcCtD
Ondansetron—Constipation—Prednisone—hematologic cancer	2.83e-05	0.000124	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—hematologic cancer	2.8e-05	0.000123	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—hematologic cancer	2.78e-05	0.000122	CcSEcCtD
Ondansetron—Dizziness—Triamcinolone—hematologic cancer	2.77e-05	0.000122	CcSEcCtD
Ondansetron—Cough—Epirubicin—hematologic cancer	2.76e-05	0.000121	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—hematologic cancer	2.76e-05	0.000121	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—hematologic cancer	2.76e-05	0.000121	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—hematologic cancer	2.74e-05	0.000121	CcSEcCtD
Ondansetron—Feeling abnormal—Prednisone—hematologic cancer	2.72e-05	0.00012	CcSEcCtD
Ondansetron—Asthenia—Betamethasone—hematologic cancer	2.72e-05	0.00012	CcSEcCtD
Ondansetron—Asthenia—Dexamethasone—hematologic cancer	2.72e-05	0.00012	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—hematologic cancer	2.72e-05	0.000119	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—hematologic cancer	2.71e-05	0.000119	CcSEcCtD
Ondansetron—Gastrointestinal pain—Prednisone—hematologic cancer	2.7e-05	0.000119	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—hematologic cancer	2.7e-05	0.000118	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—hematologic cancer	2.69e-05	0.000118	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—hematologic cancer	2.69e-05	0.000118	CcSEcCtD
Ondansetron—Pruritus—Dexamethasone—hematologic cancer	2.69e-05	0.000118	CcSEcCtD
Ondansetron—Pruritus—Betamethasone—hematologic cancer	2.69e-05	0.000118	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—hematologic cancer	2.68e-05	0.000118	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.68e-05	0.000118	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—hematologic cancer	2.66e-05	0.000117	CcSEcCtD
Ondansetron—Vomiting—Triamcinolone—hematologic cancer	2.66e-05	0.000117	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—hematologic cancer	2.64e-05	0.000116	CcSEcCtD
Ondansetron—Rash—Triamcinolone—hematologic cancer	2.64e-05	0.000116	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—hematologic cancer	2.64e-05	0.000116	CcSEcCtD
Ondansetron—Dermatitis—Triamcinolone—hematologic cancer	2.64e-05	0.000116	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Ondansetron—Urticaria—Prednisone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Ondansetron—Headache—Triamcinolone—hematologic cancer	2.62e-05	0.000115	CcSEcCtD
Ondansetron—Abdominal pain—Prednisone—hematologic cancer	2.61e-05	0.000115	CcSEcCtD
Ondansetron—Body temperature increased—Prednisone—hematologic cancer	2.61e-05	0.000115	CcSEcCtD
Ondansetron—Diarrhoea—Dexamethasone—hematologic cancer	2.6e-05	0.000114	CcSEcCtD
Ondansetron—Diarrhoea—Betamethasone—hematologic cancer	2.6e-05	0.000114	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—hematologic cancer	2.59e-05	0.000114	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—hematologic cancer	2.59e-05	0.000114	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—hematologic cancer	2.58e-05	0.000113	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—hematologic cancer	2.58e-05	0.000113	CcSEcCtD
Ondansetron—Cough—Doxorubicin—hematologic cancer	2.56e-05	0.000112	CcSEcCtD
Ondansetron—Shock—Epirubicin—hematologic cancer	2.54e-05	0.000112	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—hematologic cancer	2.54e-05	0.000112	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—hematologic cancer	2.54e-05	0.000111	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—hematologic cancer	2.52e-05	0.000111	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—hematologic cancer	2.51e-05	0.00011	CcSEcCtD
Ondansetron—Dizziness—Dexamethasone—hematologic cancer	2.51e-05	0.00011	CcSEcCtD
Ondansetron—Dizziness—Betamethasone—hematologic cancer	2.51e-05	0.00011	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—hematologic cancer	2.5e-05	0.00011	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—hematologic cancer	2.49e-05	0.000109	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—hematologic cancer	2.48e-05	0.000109	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.48e-05	0.000109	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—hematologic cancer	2.47e-05	0.000108	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—hematologic cancer	2.46e-05	0.000108	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—hematologic cancer	2.46e-05	0.000108	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—hematologic cancer	2.44e-05	0.000107	CcSEcCtD
Ondansetron—Hypersensitivity—Prednisone—hematologic cancer	2.44e-05	0.000107	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—hematologic cancer	2.42e-05	0.000106	CcSEcCtD
Ondansetron—Vomiting—Betamethasone—hematologic cancer	2.41e-05	0.000106	CcSEcCtD
Ondansetron—Vomiting—Dexamethasone—hematologic cancer	2.41e-05	0.000106	CcSEcCtD
Ondansetron—Rash—Dexamethasone—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Rash—Betamethasone—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Dermatitis—Dexamethasone—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Dermatitis—Betamethasone—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.39e-05	0.000105	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—hematologic cancer	2.38e-05	0.000105	CcSEcCtD
Ondansetron—Headache—Betamethasone—hematologic cancer	2.38e-05	0.000104	CcSEcCtD
Ondansetron—Headache—Dexamethasone—hematologic cancer	2.38e-05	0.000104	CcSEcCtD
Ondansetron—Asthenia—Prednisone—hematologic cancer	2.37e-05	0.000104	CcSEcCtD
Ondansetron—Pain—Methotrexate—hematologic cancer	2.36e-05	0.000104	CcSEcCtD
Ondansetron—Shock—Doxorubicin—hematologic cancer	2.35e-05	0.000103	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—hematologic cancer	2.35e-05	0.000103	CcSEcCtD
Ondansetron—Pruritus—Prednisone—hematologic cancer	2.34e-05	0.000103	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—hematologic cancer	2.33e-05	0.000103	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—hematologic cancer	2.32e-05	0.000102	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—hematologic cancer	2.32e-05	0.000102	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—hematologic cancer	2.3e-05	0.000101	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—hematologic cancer	2.3e-05	0.000101	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—hematologic cancer	2.28e-05	0.0001	CcSEcCtD
Ondansetron—Diarrhoea—Prednisone—hematologic cancer	2.26e-05	9.94e-05	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—hematologic cancer	2.26e-05	9.93e-05	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—hematologic cancer	2.24e-05	9.82e-05	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.23e-05	9.81e-05	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—hematologic cancer	2.23e-05	9.79e-05	CcSEcCtD
Ondansetron—Pain—Epirubicin—hematologic cancer	2.21e-05	9.71e-05	CcSEcCtD
Ondansetron—Constipation—Epirubicin—hematologic cancer	2.21e-05	9.71e-05	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—hematologic cancer	2.19e-05	9.64e-05	CcSEcCtD
Ondansetron—Dizziness—Prednisone—hematologic cancer	2.19e-05	9.6e-05	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—hematologic cancer	2.18e-05	9.6e-05	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—hematologic cancer	2.18e-05	9.6e-05	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—hematologic cancer	2.15e-05	9.44e-05	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—hematologic cancer	2.13e-05	9.37e-05	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—hematologic cancer	2.13e-05	9.36e-05	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—hematologic cancer	2.13e-05	9.34e-05	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—hematologic cancer	2.11e-05	9.29e-05	CcSEcCtD
Ondansetron—Vomiting—Prednisone—hematologic cancer	2.1e-05	9.23e-05	CcSEcCtD
Ondansetron—Rash—Prednisone—hematologic cancer	2.08e-05	9.16e-05	CcSEcCtD
Ondansetron—Dermatitis—Prednisone—hematologic cancer	2.08e-05	9.15e-05	CcSEcCtD
Ondansetron—Headache—Prednisone—hematologic cancer	2.07e-05	9.1e-05	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.07e-05	9.07e-05	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—hematologic cancer	2.06e-05	9.06e-05	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—hematologic cancer	2.05e-05	9.02e-05	CcSEcCtD
Ondansetron—Pain—Doxorubicin—hematologic cancer	2.05e-05	8.99e-05	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—hematologic cancer	2.05e-05	8.99e-05	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—hematologic cancer	2.04e-05	8.98e-05	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—hematologic cancer	2.04e-05	8.98e-05	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—hematologic cancer	2.04e-05	8.94e-05	CcSEcCtD
Ondansetron—Asthenia—Methotrexate—hematologic cancer	1.98e-05	8.71e-05	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—hematologic cancer	1.97e-05	8.66e-05	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.96e-05	8.59e-05	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—hematologic cancer	1.95e-05	8.59e-05	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—hematologic cancer	1.9e-05	8.37e-05	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—hematologic cancer	1.9e-05	8.35e-05	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—hematologic cancer	1.89e-05	8.31e-05	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—hematologic cancer	1.89e-05	8.31e-05	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—hematologic cancer	1.89e-05	8.3e-05	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—hematologic cancer	1.85e-05	8.15e-05	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—hematologic cancer	1.83e-05	8.04e-05	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—hematologic cancer	1.83e-05	8.03e-05	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—hematologic cancer	1.77e-05	7.77e-05	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—hematologic cancer	1.76e-05	7.74e-05	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—hematologic cancer	1.76e-05	7.72e-05	CcSEcCtD
Ondansetron—Rash—Methotrexate—hematologic cancer	1.74e-05	7.65e-05	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—hematologic cancer	1.74e-05	7.65e-05	CcSEcCtD
Ondansetron—Headache—Methotrexate—hematologic cancer	1.73e-05	7.6e-05	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—hematologic cancer	1.72e-05	7.54e-05	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—hematologic cancer	1.71e-05	7.51e-05	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—hematologic cancer	1.69e-05	7.44e-05	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—hematologic cancer	1.64e-05	7.22e-05	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—hematologic cancer	1.64e-05	7.19e-05	CcSEcCtD
Ondansetron—Rash—Epirubicin—hematologic cancer	1.63e-05	7.16e-05	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—hematologic cancer	1.63e-05	7.16e-05	CcSEcCtD
Ondansetron—Headache—Epirubicin—hematologic cancer	1.62e-05	7.12e-05	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—hematologic cancer	1.58e-05	6.95e-05	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—hematologic cancer	1.52e-05	6.68e-05	CcSEcCtD
Ondansetron—Rash—Doxorubicin—hematologic cancer	1.51e-05	6.63e-05	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—hematologic cancer	1.51e-05	6.62e-05	CcSEcCtD
Ondansetron—Headache—Doxorubicin—hematologic cancer	1.5e-05	6.58e-05	CcSEcCtD
Ondansetron—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.63e-06	4.77e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD44—hematologic cancer	3.62e-06	4.76e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NQO1—hematologic cancer	3.62e-06	4.76e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JAK2—hematologic cancer	3.59e-06	4.72e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—hematologic cancer	3.59e-06	4.72e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CD—hematologic cancer	3.56e-06	4.67e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FN1—hematologic cancer	3.55e-06	4.66e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.55e-06	4.66e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—hematologic cancer	3.52e-06	4.63e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—hematologic cancer	3.51e-06	4.61e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MDM2—hematologic cancer	3.51e-06	4.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BAD—hematologic cancer	3.5e-06	4.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKBIA—hematologic cancer	3.5e-06	4.61e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—hematologic cancer	3.49e-06	4.58e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.48e-06	4.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAP2K1—hematologic cancer	3.48e-06	4.57e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—hematologic cancer	3.48e-06	4.57e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.48e-06	4.57e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOTCH1—hematologic cancer	3.47e-06	4.56e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CD—hematologic cancer	3.46e-06	4.54e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYCS—hematologic cancer	3.46e-06	4.54e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.43e-06	4.51e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.43e-06	4.51e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYCS—hematologic cancer	3.43e-06	4.5e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.42e-06	4.5e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CB—hematologic cancer	3.41e-06	4.49e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MTOR—hematologic cancer	3.41e-06	4.49e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	3.4e-06	4.47e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CD80—hematologic cancer	3.4e-06	4.47e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—hematologic cancer	3.39e-06	4.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KIT—hematologic cancer	3.39e-06	4.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—hematologic cancer	3.39e-06	4.46e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.39e-06	4.45e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.39e-06	4.45e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	3.38e-06	4.45e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3R1—hematologic cancer	3.36e-06	4.41e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTPN11—hematologic cancer	3.33e-06	4.38e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGF2—hematologic cancer	3.31e-06	4.35e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.3e-06	4.34e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.28e-06	4.31e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	3.26e-06	4.29e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—hematologic cancer	3.26e-06	4.28e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—hematologic cancer	3.25e-06	4.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CREB1—hematologic cancer	3.23e-06	4.25e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	3.2e-06	4.21e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NUP98—hematologic cancer	3.2e-06	4.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—hematologic cancer	3.19e-06	4.19e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JAK2—hematologic cancer	3.17e-06	4.17e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	3.17e-06	4.17e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL2—hematologic cancer	3.16e-06	4.15e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6R—hematologic cancer	3.15e-06	4.14e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	3.15e-06	4.14e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—hematologic cancer	3.14e-06	4.13e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—hematologic cancer	3.13e-06	4.12e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—hematologic cancer	3.12e-06	4.1e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	3.11e-06	4.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.11e-06	4.08e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.11e-06	4.08e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—hematologic cancer	3.1e-06	4.07e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MDM2—hematologic cancer	3.1e-06	4.07e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NQO1—hematologic cancer	3.09e-06	4.07e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD44—hematologic cancer	3.09e-06	4.07e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NUP214—hematologic cancer	3.08e-06	4.05e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.06e-06	4.03e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—hematologic cancer	3.06e-06	4.02e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—hematologic cancer	3.05e-06	4.01e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—hematologic cancer	3.05e-06	4e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.03e-06	3.98e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.02e-06	3.97e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTR—hematologic cancer	3.02e-06	3.97e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—hematologic cancer	3.02e-06	3.97e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MTOR—hematologic cancer	3.01e-06	3.96e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	3.01e-06	3.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	3e-06	3.95e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	2.98e-06	3.92e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ENO2—hematologic cancer	2.96e-06	3.89e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	2.96e-06	3.89e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.96e-06	3.88e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—hematologic cancer	2.95e-06	3.88e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—hematologic cancer	2.93e-06	3.85e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYCS—hematologic cancer	2.93e-06	3.85e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.92e-06	3.84e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.92e-06	3.84e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	2.92e-06	3.84e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.91e-06	3.82e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	2.89e-06	3.79e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.88e-06	3.79e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	2.88e-06	3.78e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	2.88e-06	3.78e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.87e-06	3.78e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.86e-06	3.76e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGF2—hematologic cancer	2.86e-06	3.75e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.83e-06	3.72e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	2.82e-06	3.7e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EP300—hematologic cancer	2.81e-06	3.7e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SDC1—hematologic cancer	2.81e-06	3.69e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.8e-06	3.68e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.8e-06	3.68e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.8e-06	3.68e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.78e-06	3.65e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.78e-06	3.65e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—hematologic cancer	2.77e-06	3.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—hematologic cancer	2.77e-06	3.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—hematologic cancer	2.75e-06	3.62e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JAK2—hematologic cancer	2.74e-06	3.6e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SRC—hematologic cancer	2.74e-06	3.6e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CREBBP—hematologic cancer	2.72e-06	3.57e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.71e-06	3.56e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—hematologic cancer	2.7e-06	3.55e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—hematologic cancer	2.69e-06	3.54e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	2.68e-06	3.53e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—hematologic cancer	2.68e-06	3.52e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MDM2—hematologic cancer	2.67e-06	3.51e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	2.66e-06	3.5e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—hematologic cancer	2.64e-06	3.47e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—hematologic cancer	2.63e-06	3.46e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.62e-06	3.44e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	2.61e-06	3.43e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—hematologic cancer	2.6e-06	3.42e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MTOR—hematologic cancer	2.6e-06	3.42e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	2.6e-06	3.42e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.58e-06	3.39e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—hematologic cancer	2.58e-06	3.38e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.57e-06	3.38e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—EP300—hematologic cancer	2.55e-06	3.36e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	2.55e-06	3.35e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—hematologic cancer	2.54e-06	3.34e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	2.54e-06	3.34e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—hematologic cancer	2.54e-06	3.33e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	2.52e-06	3.31e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.5e-06	3.28e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	2.48e-06	3.26e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EP300—hematologic cancer	2.48e-06	3.26e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.47e-06	3.25e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.45e-06	3.22e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—hematologic cancer	2.45e-06	3.22e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	2.45e-06	3.21e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.44e-06	3.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	2.44e-06	3.21e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3R1—hematologic cancer	2.43e-06	3.2e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3R1—hematologic cancer	2.43e-06	3.19e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SRC—hematologic cancer	2.41e-06	3.17e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	2.41e-06	3.17e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—hematologic cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—hematologic cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NQO1—hematologic cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD44—hematologic cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—hematologic cancer	2.38e-06	3.12e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.37e-06	3.12e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.37e-06	3.12e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	2.35e-06	3.09e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—hematologic cancer	2.33e-06	3.06e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—hematologic cancer	2.33e-06	3.06e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—hematologic cancer	2.32e-06	3.05e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—hematologic cancer	2.32e-06	3.05e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—hematologic cancer	2.27e-06	2.98e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYCS—hematologic cancer	2.26e-06	2.97e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	2.25e-06	2.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—hematologic cancer	2.25e-06	2.95e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.25e-06	2.95e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—hematologic cancer	2.24e-06	2.95e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—hematologic cancer	2.24e-06	2.94e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	2.22e-06	2.92e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	2.2e-06	2.89e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	2.19e-06	2.88e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—hematologic cancer	2.16e-06	2.84e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.16e-06	2.84e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	2.16e-06	2.84e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EP300—hematologic cancer	2.14e-06	2.82e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.1e-06	2.75e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.08e-06	2.74e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	2.08e-06	2.74e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.08e-06	2.73e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.06e-06	2.71e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.03e-06	2.67e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.01e-06	2.65e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.01e-06	2.64e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2e-06	2.63e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—hematologic cancer	2e-06	2.63e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.99e-06	2.62e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—hematologic cancer	1.94e-06	2.55e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—hematologic cancer	1.94e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.93e-06	2.53e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—hematologic cancer	1.93e-06	2.53e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.92e-06	2.52e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.91e-06	2.51e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.89e-06	2.48e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.89e-06	2.48e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.87e-06	2.45e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.86e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—EP300—hematologic cancer	1.85e-06	2.43e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.85e-06	2.43e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—EP300—hematologic cancer	1.85e-06	2.43e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.84e-06	2.42e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.84e-06	2.41e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.83e-06	2.41e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.83e-06	2.41e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.83e-06	2.4e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.81e-06	2.38e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—hematologic cancer	1.8e-06	2.37e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—hematologic cancer	1.79e-06	2.35e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—hematologic cancer	1.78e-06	2.34e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.76e-06	2.31e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.73e-06	2.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.73e-06	2.27e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.71e-06	2.25e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.7e-06	2.23e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—hematologic cancer	1.7e-06	2.23e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.63e-06	2.15e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—hematologic cancer	1.63e-06	2.14e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.62e-06	2.13e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.59e-06	2.09e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.59e-06	2.08e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.58e-06	2.08e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.55e-06	2.03e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—hematologic cancer	1.54e-06	2.03e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.53e-06	2.02e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—hematologic cancer	1.53e-06	2.01e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—hematologic cancer	1.5e-06	1.97e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.47e-06	1.93e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.46e-06	1.92e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.4e-06	1.84e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—hematologic cancer	1.38e-06	1.81e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.37e-06	1.8e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.37e-06	1.79e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—hematologic cancer	1.36e-06	1.79e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.36e-06	1.79e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.35e-06	1.77e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—EP300—hematologic cancer	1.31e-06	1.73e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—EP300—hematologic cancer	1.3e-06	1.71e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.29e-06	1.7e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.26e-06	1.66e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.19e-06	1.57e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—hematologic cancer	1.18e-06	1.55e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—hematologic cancer	1.17e-06	1.53e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.13e-06	1.48e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—hematologic cancer	1.12e-06	1.47e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—hematologic cancer	1.12e-06	1.47e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—EP300—hematologic cancer	1.11e-06	1.46e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.04e-06	1.37e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—hematologic cancer	9.71e-07	1.28e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—hematologic cancer	9.63e-07	1.27e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—hematologic cancer	9e-07	1.18e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—EP300—hematologic cancer	8.58e-07	1.13e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—hematologic cancer	8.23e-07	1.08e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—hematologic cancer	7.93e-07	1.04e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—hematologic cancer	7.86e-07	1.03e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—hematologic cancer	6.72e-07	8.83e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.35e-07	8.34e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—hematologic cancer	5.19e-07	6.82e-06	CbGpPWpGaD
